Federal Circuit Affirms PTAB Ruling That Prior Art and FDA Skepticism Supports Non-Obviousness Finding
This Week on Capitol Hill: Senate Examines Effect of IP on Drug Prices Again, House IP Subcommittee Talks USPTO Oversight